Price
CHART BY
Frequently asked questions
What is Corcept's market capitalization?
The market capitalization of Corcept is $12.42B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is Corcept's Price-to-Earnings (P/E) ratio?
The Price-to-Earnings (P/E) ratio (TTM) for Corcept is 274.47. This ratio helps investors assess whether a stock is overvalued or undervalued compared to its earnings.
What is the Earnings Per Share (EPS) for Corcept?
Corcept's Earnings Per Share (EPS) over the trailing twelve months (TTM) is $0.419. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Corcept's stock?
Currently, 7 analysts cover Corcept's stock, with a consensus target price of $141.00. Analyst ratings provide insights into the stock's expected performance.
What is Corcept's revenue over the trailing twelve months?
Over the trailing twelve months, Corcept reported a revenue of $830.81M.
What is the EBITDA for Corcept?
Corcept's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is $8.83M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Corcept?
Corcept has a free cash flow of $106.92M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Corcept have, and what sector and industry does it belong to?
Corcept employs approximately 730 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Corcept's shares?
The free float of Corcept is 95.79M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $12.42B
- EPS (TTM)
- $0.419
- Free Float
- 95.79M
- P/E ratio (TTM)
- 274.47
- Revenue (TTM)
- $830.81M
- EBITDA (TTM)
- $8.83M
- Free Cashflow (TTM)
- $106.92M
Pricing
- 1D span
- $109.44$117.80
- 52W span
- $28.68$126.09
Analyst Ratings
The price target is $141.00 and the stock is covered by 7 analysts.
Buy
5
Hold
1
Sell
1
Information
Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.
- Employees
- 730
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- CORT
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet